ClinicalTrials.gg
RecruitingNCT07822321BLOOMUpdated Sep 16, 2026

Brexanolone Lifting Outcomes Of Moms

A Phase 3 interventional study of LPCN 1154A and Placebo in Depression, Postpartum, Postpartum Depression (PPD) and Post-partum Depression, sponsored by Lipocine Inc.. Recruiting at 16 sites in United States. Open to female participants aged 15 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Lipocine Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
15 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Planned enrollment
78th of 198
120 · median 86
Started
2026
with 13 others
Phase 3
12 of 220
1 open now
Primary completion
2027-08
later than 26 of 48 live
Registered
216th of 220
by date

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 78th largest by planned enrollment of the 198 interventional ones that give a count, is one of 14 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 26 of the 48 other live ones, and was the 216th registered.

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 15 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine:

  • If LPCN 1154A reduces depressive symptoms in subjects with severe PPD
  • How well LPCN 1154A is tolerated and what side effects it may cause
03

Conditions studied

  • Depression, Postpartum
  • Postpartum Depression (PPD)
  • Post-partum Depression
  • Postnatal Depression
  • Post-Natal Depression
  • Peripartum Depression

Keywords

  • Postpartum Depression
  • PPD
  • Depression
  • LPCN 1154A
  • brexanolone
  • neuroactive steriod
  • GABAA
04

Who can participate

Ages eligible
15 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Are female between 15 and 45 years of age, inclusive;
  • Have had a depressive episode that began no earlier than second trimester and no later than the first 4 weeks following delivery
  • Are \< 18 months postpartum at Screening
  • Hamilton Depression Rating Scale (HAM-D) 17-item score indicative of severe depression

Key Exclusion Criteria:

  • Have a history of bipolar disorder, schizophrenia or schizoaffective disorder
  • Are currently experiencing active psychosis per Investigator assessment
  • Have a history of suicidal behavior associated with the current depressive episode
  • Have a history of seizure within six months of Screening
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    LPCN 1154A Tablets

    LPCN 1154A Tablets

    Drug: LPCN 1154A

  • Placebo comparator
    Placebo Tablets

    Placebo Tablets

    Drug: Placebo

Interventions

  • Oral LPCN 1154A tablets for 48 hours

    Also known as: Brexanolone

  • DrugPlacebo

    Oral Placebo Tablets for 48 hours

06

What researchers measure

Primary outcomes

  1. Change from baseline in HAM-D17 total score compared to placebo

    The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and activities, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, genital symptoms, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: Baseline to Hour 60

Secondary outcomes

  1. Change from baseline in HAM-D17 total score

    The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and activities, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, genital symptoms, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: Baseline to Hour 12 and Day 30

  2. Change from baseline Clinical Global Impression of Severity (CGI-S) scale positive response

    The CGI-S scale is a 7-point scale that requires the Investigator to assess the severity of a patient's illness. Scores range from 1 -normal, not at all ill to 7 - among the most extremely ill patients

    Time frame: Baseline to Hour 12, Hour 60 and Day 30

07

Study locations

16 of 16 sites recruiting
  • Lipocine Investigational Site
    Tucson, Arizona 85715, United States
    Recruiting
  • Lipocine Investigational Site
    Canoga Park, California 91304, United States
    Recruiting
  • Lipocine Investigational Site
    Walnut Creek, California 94596, United States
    Recruiting
  • Lipocine Investigational Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Lipocine Investigational Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Lipocine Investigational Site
    Idaho Falls, Idaho 83402, United States
    Recruiting
  • Lipocine Investigational Site
    Chicago, Illinois 60641, United States
    Recruiting
  • Lipocine Investigational Site
    New Orleans, Louisiana 70115, United States
    Recruiting
  • Lipocine Investigational Site
    Las Vegas, Nevada 89119, United States
    Recruiting
  • Lipocine Investigational Site
    Princeton, New Jersey 08540, United States
    Recruiting
  • Lipocine Investigational Site
    Manhattan, New York 10036, United States
    Recruiting
  • Lipocine Investigational Site
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Lipocine Investigational Site
    Plano, Texas 75093, United States
    Recruiting
  • Lipocine Investigational Site
    Richardson, Texas 75080, United States
    Recruiting
  • Lipocine Investigational Site
    Clinton, Utah 84105, United States
    Recruiting
  • Lipocine Investigational Site
    Orem, Utah 84058, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 16, 2026
StartEst.
Sep 2026
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07822321
Lead sponsor
Lipocine Inc.
Responsible party
Sponsor
First posted
Sep 16, 2026
Start date
Sep 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Vice President of Clinical Development
Contact
siteinquiry@lipocine.com
801-519-4363 ext. 2116

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion